<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125211</url>
  </required_header>
  <id_info>
    <org_study_id>YK2019L01P-Ⅰ</org_study_id>
    <nct_id>NCT05125211</nct_id>
  </id_info>
  <brief_title>Safety,Tolerability,and Pharmacokinetics Profiles of GB001 Recombinant Peptide Spray in Healthy Subjects</brief_title>
  <official_title>A PhaseⅠRandomised, Double-blind, Placebo-controlled, Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Characteristics of the Oral Topical Use of GB001 Recombinant Peptide Spray in Chinese Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Echon Biopharm Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Echon Biopharm Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in China. The aim of this clinical trial is to assess the safety ,&#xD;
      tolerability and pharmacokinetics profiles of GB001 by single ascending dose and multiple&#xD;
      ascending doses in healthy subjects after topical buccal delivery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2021</start_date>
  <completion_date type="Anticipated">April 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 20, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through the study completion, an average of 2 weeks</time_frame>
    <description>The number and the incidence of serious and non-serious adverse events observed in each treatment will be used to assess the safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Characteristics， t½ of GB001 recombinant peptide</measure>
    <time_frame>Up to 240 minutes after last dose</time_frame>
    <description>Apparent terminal phase half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Characteristics , Cmax of GB001 recombinant peptide</measure>
    <time_frame>Up to 240 minutes after last dose</time_frame>
    <description>Maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Characteristics , Tmax of GB001 recombinant peptide</measure>
    <time_frame>Up to 240 minutes after last dose</time_frame>
    <description>Time of maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Characteristics , AUC of GB001 recombinant peptide</measure>
    <time_frame>Up to 240 minutes after last dose</time_frame>
    <description>Area under the plasma concentration versus time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Characteristics , Vd of GB001 recombinant peptide</measure>
    <time_frame>Up to 240 minutes after last dose</time_frame>
    <description>Apparent distribution volume</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics Characteristics , Ctrough of GB001 recombinant peptide</measure>
    <time_frame>Up to 240 minutes after last dose</time_frame>
    <description>Trough plasma concentration</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Oral retention time</measure>
    <time_frame>Up to 120 minute after first dose</time_frame>
    <description>Oral retention time</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Single dose-escalation of GB001 recombinant peptide spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive one single administration of GB001 recombinant peptide. The dosage of each group is 0.054mg, 0.108mg, 0.216mg, 0.432mg and 0.864mg, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral retention time test for a single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will receive one single administration of GB001 recombinant peptide. The dosage of the group is 0.108mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose of GB001 recombinant peptide spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each subject will be dosed with oral spray of GB001 recombinant peptide ten times per day for four days. GB001 recombinant peptide will be administrated, and the dosage of each group is 0.108mg, 0.216mg and 0.432mg, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GB001 recombinant peptide spray</intervention_name>
    <description>administrated oral spray</description>
    <arm_group_label>Multiple Ascending Dose of GB001 recombinant peptide spray</arm_group_label>
    <arm_group_label>Oral retention time test for a single dose</arm_group_label>
    <arm_group_label>Single dose-escalation of GB001 recombinant peptide spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>administrated oral spray</description>
    <arm_group_label>Multiple Ascending Dose of GB001 recombinant peptide spray</arm_group_label>
    <arm_group_label>Single dose-escalation of GB001 recombinant peptide spray</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males or females aged 18 to 45 years, with a body mass index(BMI) 19-26kg/m2&#xD;
             and body weight no less than 45 kg (female) or 50 kg (male).&#xD;
&#xD;
          2. The results in the screening examinations (including general physical examination,&#xD;
             vital signs, laboratory examinations, electrocardiogram, chest radiograph, etc.) are&#xD;
             in the normal range, or are abnormal without clinical significance assessed by the&#xD;
             investigator.&#xD;
&#xD;
          3. Subjects and their sexual partners agree to take effective contraceptive measures&#xD;
             during the study period and at least 3 days after the end of the study.&#xD;
&#xD;
          4. Understanding and willing to comply strictly with the clinical trial protocol,&#xD;
             complete all test procedures required in this trial, understand and sign informed&#xD;
             consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those allergic to GB001 peptide or any other drugs, or suffered from allergic disease&#xD;
             or allergic constitution.&#xD;
&#xD;
          2. Any obvious clinical symptoms or abnormal test results with clinical significance&#xD;
             suggested organ or system illness, unsuitable for inclusion in this trial in the&#xD;
             investigator's judgement.&#xD;
&#xD;
          3. Subjects has obvious oral lesions or diseases, such as erosion of oral mucosa, ulcer&#xD;
             or obvious periodontitis.&#xD;
&#xD;
          4. The weekly alcohol intake in 90 days before screening is more than 21 units (male) and&#xD;
             more than 14 units (female) , or the subject is unwilling to stop drinking whenever&#xD;
             required for the trial procedure.&#xD;
&#xD;
          5. Subject who smoke more than 10 cigarettes per day or is unwilling to stop smoking&#xD;
             whenever required for the trial procedure.&#xD;
&#xD;
          6. Subject with a history of drug abuse, or those with positive urine screening test for&#xD;
             drug abuse.&#xD;
&#xD;
          7. Subject who use of any other drugs within 30 days prior to screening, including&#xD;
             prescription drugs, non-prescription drugs, biologicals, vitamins, minerals and&#xD;
             nutritional supplements.&#xD;
&#xD;
          8. Blood loss or blood donation more than 400 mL within 90 days prior to screening.&#xD;
&#xD;
          9. Received major surgery within 90 days prior to screening, or participated in any other&#xD;
             drug/device clinical trial.&#xD;
&#xD;
         10. Pregnant or lactating women; or female subject of childbearing age have a positive&#xD;
             serum pregnancy test result during the screening.&#xD;
&#xD;
         11. Subject with dizzy needle or difficulty in venous blood collection.&#xD;
&#xD;
         12. Subject unsuitable for the trial in the judgement of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Feng Shao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junfeng Han, MD</last_name>
    <phone>086-0571-86053167</phone>
    <email>ykmd@genloci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanjing medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Feng Shao, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 24, 2021</study_first_submitted>
  <study_first_submitted_qc>November 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 7, 2021</last_update_submitted>
  <last_update_submitted_qc>November 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

